Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation. Issue 7 (7th June 2022)

• Record Type: Journal Article
• Authors: Nagayama, Takashi; Fujiwara, Shin-ichiro; Kikuchi, Tomohiro; Onda, Kaoru; Murahashi, Rui; Nakashima, Hirotomo; Ikeda, Takashi; Matsuoka, Sae; Kawaguchi, Shin-ichiro; Toda, Yumiko; Ito, Shoko; Ban, Tetsuaki; Umino, Kento; Minakata, Daisuke; Nakano, Hirofumi; Yamasaki, Ryoko; Morita, Kaoru; Ashizawa, Masahiro; Yamamoto, Chihiro; Hatano, Kaoru; Sato, Kazuya; Oh, Iekuni; Ohmine, Ken; Kanda, Yoshinobu
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 7(2022)
• Page Start: 1694
• Page End: 1700
• Publication Date: 2022-06-07
• Subjects: Sarcopenia -- skeletal muscle mass loss -- allo-HCT -- CT; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2034159
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The definition of sarcopenia assessed by computed tomography (CT) varies among different reports, and few studies have examined the effect of muscle mass loss on the prognosis of post-hematopoietic cell transplantation (HCT). We retrospectively evaluated 172 patients who underwent an initial allogeneic HCT for acute leukemia at our institution. They were divided into 3 groups according to muscle mass measured at the third lumbar vertebra as assessed by CT. Patients with low muscle mass had a worse performance status, higher comorbidity index and higher disease risk. There was a significant difference in 2-year overall survival between the 3 groups, and worse overall survival (OS) was associated with lower muscle mass ( p = 0.005). Muscle mass loss did not affect non-relapse mortality ( p = 0.238) but was significantly associated with relapse ( p = 0.067). Pre-transplant muscle mass loss may therefore reflect a poor prognosis for the primary disease.